2029-94-9

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Diethoxybenzaldehyde is used as a key intermediate in the synthesis of pharmaceutical compounds due to its chemical reactivity and structural properties. Its potential as an anti-inflammatory and analgesic agent has made it a promising candidate for further development in drug discovery.
Used in Fragrance Industry:
3,4-Diethoxybenzaldehyde is used as a fragrance ingredient for its pleasant and appealing odor. It contributes to the creation of perfumes and other scented products, enhancing their overall aroma profile.
Used in Research and Development:
3,4-Diethoxybenzaldehyde is utilized in scientific research for studying its chemical properties, potential applications, and effects on biological systems. This includes investigations into its anti-inflammatory and analgesic properties, as well as its potential use in drug delivery systems.
Safety Considerations:
It is important to handle 3,4-Diethoxybenzaldehyde with care, as it has the potential to cause skin and eye irritation. Proper safety measures, such as wearing protective gear and working in well-ventilated areas, should be taken to minimize risks associated with its use.

InChI:InChI=1/C11H14O3/c1-3-13-10-6-5-9(8-12)7-11(10)14-4-2/h5-8H,3-4H2,1-2H3

Upstream product

• 121-32-4 4-hydroxy-3-ethoxybenzaldehyde 
• 64-67-5 diethyl sulfate 
• 2539-53-9 4-ethoxy-3-hydroxybenzaldehyde 
• 2050-46-6 1,2-diethoxybenzene 
• 75-03-6 ethyl iodide 
• 93-61-8 N-methyl-N-phenylformamide 
• 74-96-4 ethyl bromide 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 120-80-9 benzene-1,2-diol 
• 100-97-0 hexamethylenetetramine 
• 99272-94-3 2-ethoxy-4-(prop-1-en-1-yl)phenol 
• 63477-41-8 trans-2-ethoxy-5-(1-propenyl)-phenol 
• 2029-95-0 1,2-diethoxy-4-trans-propenyl-benzene 

Downstream Products

• 92582-04-2 3-((Ξ)-3,4-diethoxy-benzylidene)-dihydro-furan-2-one 
• 97016-66-5 (3,4-diethoxy-benzyl)-(5-piperidino-pentyl)-amine 
• 65383-59-7 3,4-diethoxyphenol 
• 103046-00-0 3,4-diethoxy-4'-phenyl-trans-chalcone 
• 101579-53-7 (E)-N’-(3',4'-diethoxybenzylidene)isonicotinohydrazide 
• 131981-72-1 1,2-diethoxy-4-(2-nitro-cis-propenyl)-benzene 
• 109399-76-0 2-((Z)-3,4-diethoxy-benzylidene)-6-hydroxy-4-methoxy-benzofuran-3-one 
• 102660-84-4 2-(3,4-diethoxy-trans-styryl)-8-methoxy-3H-quinazolin-4-one 
• 40665-54-1 1-(3,4-diethoxy-phenyl)-2-nitro-ethanol 
• 40665-53-0 (E)-3,4-diethoxy-β-nitro-styrene 
• 137013-00-4 3,4-diethoxycinnamic acid 

Relevant academic research and scientific papers

Modular logic gates: Cascading independent logic gates via metal ion signals

Systematic cascading of molecular logic gates is an important issue to be addressed for advancing research in this field. We have demonstrated that photochemically triggered metal ion signals can be utilized towards that goal. Thus, independent logic gates were shown to work together while keeping their identity in more complex logic designs. Communication through the intermediacy of ion signals is clearly inspired from biological processes modulated by such signals, and implemented here with ion responsive molecules.

ISOINDOLE DERIVATIVE

Disclosed is a compound of formula (I) and a stereoisomer thereof: wherein R1, R2, R3 and R4 are as defined in the present disclosure.

In vitro study and structure-activity relationship analysis of stilbenoid derivatives as powerful vasorelaxants: Discovery of new lead compound

The development of vasorelaxant as the antihypertensive drug is important as it produces a rapid and direct relaxation effect on the blood vessel muscles. Resveratrol (RV), as the most widely studied stilbenoid and the lead compound, inducing the excellent vasorelaxation effect through the multiple signalling pathways. In this study, the in vitro vascular response of the synthesized trans-stilbenoid derivatives, SB 1-8e were primarily evaluated by employing the phenylephrine (PE)-precontracted endothelium-intact isolated aortic rings. Herein we report trans-3,4,4′-trihydroxystilbene (SB 8b) exhibited surprisingly more than 2-fold improvement to the maximal relaxation (Rmax) of RV. This article also highlights the characterization of the aromatic protons in terms of their unique splitting patterns in 1H NMR.

Peripheral Substitution of Tetraphenyl Porphyrins: Fine-Tuning Self-Assembly for Enhanced Electroluminescence

This study reports the synthesis of two novel zinc porphyrin families bearing four or eight alkoxy chains at their peripheral phenyl rings, with the length of the alkoxy chains ranging from 2, to 6, and to 12 carbon atoms. All zinc porphyrin derivatives were fully characterized with respect to their photophysical and electrochemical features. The zinc porphyrins could be processed into thin films which, depending on the length of the alkoxy chains on the aryl substituents, were found to be either of an ordered or a disordered nature, as it is revealed by spectroscopic and microscopic techniques. The films containing ordered self-assemblies displayed significantly enhanced electrical conductivity compared to the disordered films. This led to remarkable differences regarding their electroluminescence response that occurs at lower bias. Furthermore, their luminous efficiency was of almost one order of magnitude higher than that of disordered films.

Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy

A series of new (-)-arctigenin derivatives with variably modified O-alkyl groups were synthesized and their preferential cytotoxicity was evaluated against human pancreatic cancer cell line PANC-1 under nutrient-deprived conditions. The results showed that monoethoxy derivative 4i (PC50, 0.49 μM), diethoxy derivative 4h (PC50, 0.66 μM), and triethoxy derivative 4m (PC50, 0.78 μM) showed the preferential cytotoxicities under nutrient-deprived conditions, which were identical to or more potent than (-)-arctigenin (1) (PC50, 0.80 μM). Among them, we selected the triethoxy derivative 4m and examined its in vivo antitumor activity using a mouse xenograft model. Triethoxy derivative 4m exhibited also in vivo antitumor activity with the potency identical to or slightly more than (-)-arctigenin (1). These results would suggest that a modification of (-)-arctigenin structure could lead to a new drug based on the antiausterity strategy.

Exquisite synthesis of a designed PAR-1 antagonist

The synthesis of a designed, sterically congested geminal dimethyl-bearing PAR-1 antagonist was achieved by a route of ten steps, with the oxidation of an electron-rich benzaldehyde, the construction of a tertiary alkyl azide, and the selective hydrogenolysis of a 1,5-fused tetrazole to generate the cyclic amidine with Raney-Ni being the key steps. The selective hydrogenolysis of 1,5-fused tetrazole to generate the cyclic amidine with Raney-Ni was discovered and may be generally used for the synthesis of structurally unusual cyclic amidines. Several unsuccessful attempts to construct the desired geminal dimethyl-bearing cyclic amidine were also discussed. Copyright

HYDRAZIDE DERIVATIVES

A compound represented by the following general formula (1) or a salt thereof or a hydrate of the foregoing is safe while exhibiting suitable physicochemical stability, and is useful as therapeutic or prophylactic agents for diseases associated with thrombus formation. wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc., R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc., Z1, Z2 and Z3 each independently represent hydrogen, etc., Z4 represents hydrogen, etc. and X represents a single bond or -CO-, etc.

Cyclic compounds and uses thereof

Compounds of general formula (1) R1—X1—W—X2—Z1—Z2—R2 or salts thereof, exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1is an optionally substituted five- or six-membered ring group; X1is a free valency or the like; W is a divalent group represented by, e. g., general formula (2) (wherein A and B are each an optionally substituted five- to seven-membered ring; E1and E4are each optionally substituted carbon or the like; E2and E3are each oxygen or the like; and a and b are each a single bond or a double bond); X2is a divalent group constituting a straight chain moiety; Z1is a divalent cyclic group or the like; Z2is a free valency or the like; and R2is optionally substituted amino or the like.

Compositions containing aromatic aldehydes and their use in treatments

Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.

Serine protease inhibitors

Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5and R6are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.